Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05617599 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SUPRAFLEX CRUZ PMCF Study ( rEpic05 )

Study acronym: Multiflex
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 1, 2025 to Dec 1, 2026v15
  2. Primary completion date: Dec 1, 2024 to Dec 1, 2025 Completion date: Oct 1, 2025 to Dec 1, 2025v14 Show 1 more changeShow less
    • Completion date: Oct 1, 2025 to Dec 1, 2025
  3. Study sites: 20 to 21v13
  4. Study sites: 18 to 20v12
  5. Study sites: 17 to 18v11
Show 9 earlier versionsHide 9 earlier versions
  1. Study sites: 16 to 17v10
  2. Study sites: 14 to 16v9
  3. Study sites: 11 to 14v8
  4. Study sites: 10 to 11v7
  5. Study sites: 8 to 10v6
  6. Study sites: 7 to 8v5
  7. Study sites: 4 to 7v4
  8. Study sites: 3 to 4v3
  9. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 1, 2022 to May 10, 2023 · Study sites: 0 to 3v2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 1, 2022 to May 10, 2023
    • Study sites: 0 to 3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Medical Device Regulations (MDR) with multivessel coronary disease requirements in all the CONSECUTIVE patients treated with (SUPRAFLEX CRUZ).
Trial Details
NCT Number NCT05617599
Lead Sponsor Fundación EPIC
Conditions Coronary Artery Disease (CAD), Ischemic Heart Disease
Enrollment 508 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov